

**09 / 4 23712**

**420 Rec'd PCT/PTO 09 NOV 1999**

**PATENT APPLICATION  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**TISSUE FACTOR FOR INFLUENCING BLOOD VESSEL FORMATION**

**Inventors:**

**Peter Nawroth  
Katsumi Nakagawa  
Youming Zhang**

**PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711**

**(650) 493-4935**

**Attorney Docket No.: 8484-075-999**

09423712 082500

09 / 4 23712

420 Rec'd PCT/PTO 09 NOV 1999

TABLE OF CONTENTS

I.	FIELD OF THE INVENTION .....	- 1 -
II.	BACKGROUND OF THE INVENTION .....	- 1 -
III.	SUMMARY OF THE INVENTION .....	- 2 -
IV.	BRIEF DESCRIPTION OF THE DRAWINGS .....	- 2 -
V.	DETAILED DESCRIPTION OF THE INVENTION .....	- 2 -
VI.	EXAMPLE .....	- 6 -
WHAT IS CLAIMED: .....		- 8 -
ABSTRACT .....		- 11 -

0943312.082500  
005230" 2T/22460

5/PRTS

09/423712 ~~11-6~~  
420 Rec'd PCT/PTO 09 NOV 1999 ~~11-24-99~~  
KP

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**TISSUE FACTOR FOR INFLUENCING BLOOD VESSEL FORMATION**

5

This is a national phase filing of the Application No. PCT/DE98/01306, which was filed with the Patent Corporation Treaty on May 8, 1998, and is entitled to priority of the German Patent Application 197 19 652.7 filed May 9, 1997.

**I. FIELD OF THE INVENTION**

The present invention relates to the use of tissue factor for influencing blood vessel formation, particularly for activating blood vessel formation, above all for wound healing.

**II. BACKGROUND OF THE INVENTION**

15 The body is provided with blood by means of blood vessels. Blood vessels comprise endothelial and smooth muscle cells. In many diseases, blood vessels and the formation thereof, respectively, are impaired. This is found, *e.g.*, in impaired wound healing as in the case of diabetes mellitus, vasculitis, arterial occlusive disease, chronic venous and infected ulcer. There are also major problems in connection with wound healing in the case of  
20 innervation impairment such as paraplegia, leprosy, neuropathy, etc., and decubital gangrene of persons in need of care. Also known are weak sutures and wound healing impairment in the case of operations, particularly of the intestines and transplantations of skin or other organs, respectively. Up to the present, there are no satisfactory products or means by which it is possible to take steps in the case of blood vessel diseases, in particular impaired  
25 wound healing.

Therefore, it is the object of the present invention to provide a product by means of which the above objective can be achieved.

30

### III. SUMMARY OF THE INVENTION

The present invention relates to the use of tissue factor for influencing blood vessel formation, particularly for activating blood vessel formation, above all for wound healing.

### 5 IV. BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 shows the formation of vessels (blood vessels) in wounds transfected with a tissue factor-expressing vector (a). (b) is a vector which codes for an antisense tissue factor, and (c) is a control.

FIGURE 2 shows the formation of vessels in wounds transfected with a tissue  
10 factor-expressing vector (a). (b) is a vector which codes for an antisense tissue factor, and (c) is a control. The blood vessels are made visible by hematoxylin/eosin staining (FIGURE 2A). In FIGURE 2B, the number of blood vessels is shown by way of diagram.

FIGURE 3 shows the presence of smooth muscle cells in newly formed vessels in  
wounds transfected with a tissue factor-expressing vector (a). (b) is a vector which codes  
15 for an antisense tissue factor, and (c) is a control. The muscle cells are made visible by  $\alpha$ -actin staining (FIGURE 3A). In FIGURE 3B, the strength of the staining is shown by way of diagram.

### V. DETAILED DESCRIPTION OF THE INVENTION

20 It is the object of the present invention to provide a product by means of which the above objective can be achieved. According to the invention this is achieved by the subject matters defined in the claims.

Thus, the subject matter of the present invention relates to the use of tissue factor for influencing blood vessel formation, in particular for activating blood vessel formation,  
25 above all for wound healing.

The present invention is based on the applicant's finding that in wounds of animals tissue factor results in the formation of vessels (blood vessels). He found out that the vessels comprise endothelial and smooth muscle cells. The applicant also recognized that wound healing can be achieved by means of tissue factor. Furthermore, the applicant  
30 discovered that vessel formation can be prevented by inhibiting tissue factor.

09423712.082500

Tissue factor is a transmembrane glycoprotein which binds the blood clotting factors VII and VITa, respectively. An activation of the blood clotting factors X and IX, respectively, is effected by this bond, so that the blood coagulation is started via the extrinsic path and intrinsic path, respectively. Tissue factor has a molecular weight of 43 to 5 46 kD. Its primary structure is known as is the gene for tissue factor and its localization on the chromosome. Scarpati *et al.*, 1987, *Biochemistry* 26:5234-5238.

According to the invention tissue factor is used for activating vessel formation, particularly for wound healing. The expression "tissue factor" relates to a tissue factor of any kind and origin. It may be an animal or human tissue factor. It can be glycosylated or 10 non-glycosylated. Also, it may be a fragment of tissue factor which is capable of forming vessels, in particular for wound healing. The tissue factor can have a wild-type sequence. Its sequence can also differ from the wild-type sequence by one or several amino acids. In addition, the tissue factor can be part of a fusion protein.

In a preferred embodiment, the tissue factor is present in the form of an expressible 15 nucleic acid. It may be a DNA and/or RNA, a DNA, particularly a genomic or cDNA and fragments thereof, respectively, being preferred. The above statements made on the tissue factor apply here correspondingly to the nucleic acid.

The expression of the nucleic acid can be achieved as usual. It can be favorable for the nucleic acid, *e.g.*, as a DNA, particularly cDNA, to be present in a vector which is 20 suitable for expression in animal cells. A person skilled in the art is familiar with such expression vectors. For example, they may be virus or plasmid vectors. It is advantageous for the vectors not to integrate into the genome of cells but remain episomally within the cells. By this, a transient expression of the tissue factor is achieved, which is preferred. The nucleic acid as a DNA, particularly cDNA, can also be controlled by a constitutive or 25 inducible promoter. An inducible promoter can be, *e.g.*, tissue-, organ- and/or tumor-specific. It can be favorable for the nucleic acid as DNA, particularly cDNA, to be controlled by the CMV promoter, *e.g.*, in the expression vector pcDNA3 (Invitrogen company) or controlled by the SV40 promoter, *e.g.*, in the expression vector pSVK3 (Pharmacia company). Such expression plasmids referred to as pcDNA3-TF (tissue factor) 30 and pSVK3-TF, respectively, also represent a subject matter of the present invention. It can be particularly advantageous for the nucleic acids as DNA, particularly cDNA, to be present

in a Sindbis virus replicon vector. Such a vector permits an extremely high expression of the nucleic acid. An example of such a vector is the ELVS vector system from Viagene Inc. An expression plasmid referred to as ELVS-TF (tissue factor) also represents a subject matter of the present invention. For the preparation of an above vector, a person skilled in  
5 the art will use known methods. Reference is made to Maniatis *et al.*, 1982, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, by way of supplement.

According to the invention tissue factor is used for activating vessel formation, in particular for wound healing. The expression "vessel formation" relates to a vessel formation of any kind and at any site. For example, it relates to a vessel formation serving  
10 for replacing impaired, *e.g.*, old, blood vessels. They can be present, *e.g.*, in the brain or heart, so that an apoplexy or infarction can be prevented or treated. Precautions can also be taken against presbyphrenia. In addition, it relates to a vessel formation for treating arteriosclerosis, Crohn's disease and ulcerative colitis, diabetic retinopathy and deep venous thrombosis of the legs/ulcus cruris as well as the prevention of relapses. In particular, it  
15 relates to vessel formation and wound healing. The expression "wound healing" relates to wound healing of any kind and at any site. It can be normal and impaired wound healing. The latter is found in particular in the case of diseases, such as diabetes mellitus, vasculitis, arterial occlusive disease, chronic venous and/or infected ulcer as well as poorly healing gastric ulcer. Impaired wound healing is also found in the case of innervation impairment  
20 such as paraplegia, leprosy, neuropathy, etc., and decubital gangrene of persons in need of care. Impaired wound healing will also be given if weak sutures and impaired healing occur after operations, particularly of the intestines and transplantations of skin and other organs, respectively. Impaired wound healing is also found in the case of bone fractures, burns and treatments using steroids.

According to the invention tissue factor is administered in the form of a protein or an  
25 expressible nucleic acid to activate vessel formation, in particular for wound healing. It may be favorable for the tissue factor to be administered in combination with further factors supporting vessel formation, in particular for wound healing, such as vascular endothelial growth factor (VEGF). These factors can also be present in the form of proteins and/or  
30 expressible nucleic acids. The tissue factor and said factors can be administered simultaneously or successively. The kind of administration of tissue factor alone and

together with said factors, respectively, can orient itself by the site of action, *i.e.*, at the site where blood vessel formation, in particular for wound healing, shall take place. For example, it is an obvious thing to treat an area on the body surface locally and one within the interior of the body systemically. Common methods can be used for the administration  
5 of tissue factor alone and together with said factors, respectively. For the local administration it is, *e.g.*, favorable to pack the factor or factors into liposomes or absorb them onto carriers, particularly gold particles, and apply the liposomes to the corresponding site of the body and shoot the carriers, particularly gold particles, into the tissue, respectively. Furthermore, pharmaceutical compositions are provided for the administration  
10 of tissue factor alone and together with said factors, respectively, which may contain common auxiliary substances such as carriers, solvents, etc. Such compositions also represent a subject matter of the present invention.

According to the invention tissue factor is also used for inhibiting blood vessel formation. For this purpose, the tissue factor can be present in the form of an antibody  
15 inhibiting it. The tissue factor can also be present in the form of a nucleic acid which has an antisense effect on the expression of tissue factor. In particular tumoral diseases can be treated by the inhibition of vessel formation.

By means of the present invention it is possible to influence vessel formation. In particular, vessel formation can be activated. The resulting blood vessels comprise  
20 endothelial and smooth muscle cells. Thus, the present invention is suited for the prevention and treatment of the most varying diseases. Examples thereof are indicated above. In particular, the present invention is suitable for the treatment and/or prophylaxis of impaired wound healing, above all in the case of diabetes mellitus, where it is possible to heal large open wounds located at the extremities. In addition, vessel formation can be  
25 inhibited by means of the present invention. Thus, the present invention is also suited to treat diseases, such as tumoral diseases. The present invention makes a major contribution to modern medicine.

The below examples explain the invention in more detail. The following  
30 preparations and examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. The present invention, however, is not

limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of the invention only, and methods which are functionally equivalent are within the scope of the invention. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

## VI. EXAMPLE

### **Preparation of a tissue factor-expressing plasmid and its use for influencing blood vessel formation, particularly for activating blood vessel formation, above all for wound healing**

10

(A) The entire translated region (1.8 kb) of the mouse tissue factor gene was integrated into the BamHI site of the multiple cloning site of pcDNA3 (Invitrogen). Thus, this region was controlled by the CMV promoter. The expression plasmid pcDNA3-TF was obtained. In the same way, the coding region (0.7 kb) of the mouse tissue factor gene was integrated in the antisense orientation into the EcoRI site of the multiple cloning site of pcDNA3. Thus, this region was also controlled by the CMV promoter. The expression plasmid pcDNA3-TF-AS was obtained.

15

6 mm full thickness wounds each were placed on the backs of three female NOD mice (Bomholtgaard, Denmark) at a distance of 8 to 10 mm. These wounds were treated with mixtures containing 2  $\mu$ g pcDNA3-TF (a), pcDNA3-TF-AS (b) and pcDNA3 (control (c)), respectively, and 12  $\mu$ g DOTAP transfection reagent (Boehringer Mannheim) each. The wounds were covered with Ohmann Opraflex.

20

For proving the formation of vessels (blood vessels) in the wounds, 300  $\mu$ l of ink (Nigrosin, Sigma) each were injected into the caudal vein of the mice 6 days and 8 days, respectively, following the administration of the mixtures. Thereafter, the animals were killed and the skin regions with the wounds were examined under a microscope.

25

It showed that if a tissue factor-expressing vector (a) is administered, vessels (blood vessels) will be formed in wounds and thus wound healing will be promoted. It also turned out that an antisense tissue factor can inhibit the formation of blood vessels.

30



(B) As described under (A), six NOD mice were treated. After 6 days and 8 days, respectively, the animals were killed and the corresponding skin regions were examined under a microscope after having been subjected to  $\alpha$ -actin staining (with Sm-actin antibodies from Dianova).

5 It showed that the blood vessels formed comprise smooth muscle cells.

All references cited within the body of the instant specification are hereby incorporated by reference in their entirety.

10

15

20

25

30